Información del artículo
En los últimos años, el tratamiento sustitutivo con hormona del crecimiento (GH) para adultos deficitarios ha pasado de representar una perspectiva a ser una indicación clínica, y ha quedado suficientemente demostrada su efectividad al revertir la mayor parte de las manifestaciones del síndrome de deficiencia de GH en el adulto. La experiencia ha permitido diferenciar entre adultos que habían presentado la deficiencia antes de finalizar el crecimiento y la pubertad y los que la presentaban posteriormente. Las diferencias no son sólo etiológicas, sino que también lo son sus características fenotípicas y la respuesta al tratamiento. En este artículo se revisan las distintas formas de presentación según el momento de instauración y los efectos sobre la composición corporal, la densidad mineral ósea, la calidad de vida relacionada con la salud y el perfil lipídico, que comporta la supresión de la GH cuando se alcanza la talla final. También se evalúan los resultados de la reintroducción del tratamiento con GH tras un período libre de tratamiento en adultos a los que se les suprime la GH al llegar a la talla final.
Palabras clave:
Déficit de hormona del crecimiento en el adulto
Hipopituitarismo
Hormona del crecimiento
Tratamiento
Composición corporal
Calidad de vida relacionada con la salud
In the last few years, growth hormone (GH) replacement therapy in GHdeficient adults has become a clinical reality and its effectiveness has been sufficiently demonstrated by its ability to reverse most of the clinical manifestations of GH deficiency syndrome in adults. Experience has allowed us to differentiate between adults presenting deficiency before the end of growth and puberty and those who subsequently become deficient. The differences are not only etiologic; phenotypic characteristics and response to treatment also differ. In the present article we review the different types of presentation according to their onset and the effects of body composition, bone mineral density, health-related quality of life, and lipid profile when GH therapy is discontinued after final height has been achieved. We also evaluate the results of the reintroduction of GH therapy in adults in whom the therapy was discontinued on reaching final height.
Key words:
Growth hormone deficiency in adults
Hypopituitarism
Growth hormone
Treatment
Body composition
Health-related quality of life
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.P. Frindik, J. Baptista.
Adult Height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study.
Pediatrics, 104 (1999), pp. 1000-1004
[2.]
T.R.C. Cuneo, F. Salomon, G.A. MacGauley, P.H. Sonksen.
The growth hormone deficiency syndrome in adults.
Clin Endocrinol (Oxf), 37 (1992), pp. 387-397
[3.]
F. Salomon, R.C. Cuneo, R. Hesp, P.H. Sonksen.
The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.
N Engl J Med, 321 (1989), pp. 1797-1803
[4.]
J.O.L. Jorgensen, L. Thuesen, T. Ingemannhansen, S. Pedersen, J. Jorgensen, N.E. Skakkebaek, et al.
Beneficial effects of growth hormone treatment in GHdeficient adults.
Lancet, 1 (1989), pp. 1221-1225
[5.]
B. Bengtsson, S. Eden, L. Lonn, H. Kvist, A. Stokland, Lindstedt, et al.
Treatment of adults with growth hormone (GH) deficiency with recombinant human GH.
J Clin Endocrinol Metab, 76 (1993), pp. 309-317
[6.]
P.V. Carroll, E.R. Christ, B.A. Bengtsson, L. Carlsson, J.S. Christiansen, D. Clemmons, et al.
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review.
J Clin Endocrinol Metab, 83 (1998), pp. 382-395
[7.]
J. Mesa, J. Gómez, C. Hernández, A. Picó, A. Ullied.
Deficiencia de hormona de crecimiento en el adulto: efectos del tratamiento sustitutivo sobre la composición corporal y la calidad de vida relacionada con la salud.
Med Clin (Barc), 120 (2003), pp. 41-46
[8.]
J. Soler Ramón, J.M. Gómez Sáez, N. Gómez Arnáiz.
Modificaciones del perfil lipídico y de función tiroidea en pacientes adultos con hipopituitarismo tras tratamiento sustitutivo con hormona de crecimiento.
Med Clin (Barc), 113 (1999), pp. 775-776
[9.]
J.M. Gómez Sáez, N. Gómez Arnáiz, J. Soler Ramón.
Cambios en la composición corporal en en pacientes con hipopituitarismo tras tratamiento sustitutivo con hormona de crecimiento.
Med Clin (Barc), 113 (1999), pp. 246-249
[10.]
M.L. Vance, N. Mauras.
Growth hormone therapy in adults and children.
N Engl J Med, 341 (1999), pp. 1206-1215
[11.]
W. Drake, S. Howell, J. Monson, S. Shalet.
Optimizing GH therapy in adults and children.
Endocrine Rev, 22 (2001), pp. 425-450
[12.]
S. Chernausek.
Managing the transition of adolescents with GH deficiency.
J Endocrinol Invest, 24 (2001), pp. 676-680
[13.]
S. Blethen, J. Baptista, J. Kuntze, T. Foley, S. LaFranchi, A. Johanson.
Adult height in growth hormone –deficient children treated with biosynthetic GH.
J Clin Endocrinol Metab, 82 (1997), pp. 418-420
[14.]
E. Cacciari, P. Tassoni, A. Cicogniani, P. Pirazzoli, S. Salardi, A. Balsamo.
Value and limits of pharmacological and phisiological tests to diagnose growth hormone deficiency and predict therapy response: first and second retesting during replacement therapy of patients defined as GH deficient.
J Clin Endocrinol Metab, 79 (1994), pp. 1663-1669
[15.]
M. Tauber, P. Moulin, C. Pienkowski, B. Jouret, P. Rochiccioli.
Growth hormone retesting and auxological data in 131 GH-deficient patients after completion of treatment.
J Clin Endocr Metab, 82 (1997), pp. 352-356
[16.]
A.F. Attanasio, S.W. Lamberts, A.M. Matranga, M.A. Birkett, P.C. Bates, N.K. Valk, et al.
Adult growth hormone deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment.
J Clin Endocrinol Metab, 82 (1997), pp. 82-88
[17.]
H. De Boer, G.J. Blok, B. Voerman, P. Derriks, E. Van der Veen.
Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men.
Int J Obes Relat Metab Disord, 20 (1996), pp. 580-587
[18.]
H. De Boer, G.J. Blok, B. Voerman, P. De Vries, C. Popp-Snijders, E. Van der Veen.
The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis.
J Clin Endocrinol Metab, 80 (1995), pp. 2069-2076
[19.]
B. Merola, A. Cittadini, A. Colao, S. Longobardi, S. Fazio, D. Sabatini, et al.
Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency.
J Clin Endocrinol Metab, 77 (1993), pp. 1658-1661
[20.]
G. Amato, C. Carella, S. Fazio, G. La Montagna, A. Cittadini, D. Sabatini, et al.
Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses.
J Clin Endocrinol Metab, 77 (1993), pp. 1671-1676
[21.]
J.M. Kaufman, P. Taelman, A. Vermeuen, M. Vandeweghe.
Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset.
J Clin Endocrinol Metab, 74 (1992), pp. 118-123
[22.]
H. De Boer, G.J. Blok, A. Van Lingen, G.J. Teule, P. Lips, E.A. Van der Veen.
Consequences of childhood-onset growth hormone deficiency for adult bone mass.
J Bone Miner Res, 9 (1994), pp. 1319-1326
[23.]
H. De Boer, G.J. Blok, H.J. Voerman, M. Phillips, J.A. Schouten.
Serum lipid levels in growth hormone-deficient men.
Metab Clin Exp, 43 (1994), pp. 199-203
[24.]
J.B. Deijen, H. De Boer, G.J. Blok, E.A. Van der Veen.
Cognitive impairments and mood disturbances in growth hormone deficient men.
Psychoneuroendocrinology, 21 (1996), pp. 313-322
[25.]
O.M. Rutherford, D.A. Jones, J.M. Round, C.R. Buchanan, M.A. Preece.
Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults.
Clin Endocrinol (Oxf), 34 (1991), pp. 469-475
[26.]
M. Colle, J. Auzerie.
Discontinuation of growth hormone therapy in growth-hormone-deficient patients: assessment of body fat mass using bioelectrical impedance.
Horm Res, 39 (1993), pp. 192-196
[27.]
G. Johannsson, K. Albertsson-Wikland, B.A. Bengtsson.
Discontinuation of growth hormone treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects.
J Clin Endocrinol Metab, 84 (1999), pp. 4516-4524
[28.]
F.J. Cowan, W. Evans, J. Gregory.
Metabolic effects of discontinuing growth hormone treatment.
Arch Dis Child, 80 (1999), pp. 517-523
[29.]
W. Gerver, R. De Bruin, W. Delemarre, B. Aldewereld, P. Theunissen, K. Westerterp.
Effects of discontinuing of growth hormone treatment on body composition and metabolism.
Horm Res, 53 (2000), pp. 215-220
[30.]
N. Vahl, A. Juul, J.O. Jorgensen, H. Orskov, N.E. Skakkebaek, J.S. Christiansen.
Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study.
J Clin Endocrinol Metab, 85 (2000), pp. 1874-1881
[31.]
V. Matkovic, T. Jelic, G. Wardlaw, J. Ilich, P. Goel, J. Wright, et al.
Timing of peak bone mass in Caucasian and its implications for prevention of osteoporosis.
J Clin Invest, 93 (1994), pp. 799-808
[32.]
S.J. Holmes, G. Economou, R.W. Whitehouse, J.E. Adams, S.M. Shalet.
Reduced bone mineral density in patients with adult onset growth hormone deficiency.
J Clin Endocrinol Metab, 78 (1994), pp. 669-674
[33.]
T. Rosen, L. Wilhelmsen, K. Landin-Wilhelmsen, G. Lappas, B.A. Bengtsson.
Increased fracture frequency in adult patients with hypopituitarism and GH deficiency.
Eur J Endocrinol, 137 (1997), pp. 240-245
[34.]
C. Wuster, R. Abs, B.A. Bengtsson, H. Bennmarker, U. Feldt-Ras-mussen, E. Hernberg-Stahl.
The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density.
J Bone Miner Res, 16 (2001), pp. 398-405
[35.]
D.J. O'Halloran, A. Tsatsoulis, R.W. Whitehouse, S.J. Holmes, J.E. Adams, S.M. Shalet.
Increased bone density after recombinant human growth hormone therapy in adults with isolated GH deficiency.
J Clin Endocrinol Metab, 76 (1993), pp. 1344-1348
[36.]
H. Fors, R. Bjarnason, L. Wirent, K. Albertsson-Wikland, L. Bosaeust, B.A. Bengtsson, et al.
Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents.
Clin Endocrinol (Oxf), 55 (2001), pp. 617-624
[37.]
W. Drake, P. Carroll, K. Maher, C. Metcalfe, C. Camacho-Hubner, N. Shaw, et al.
The effect of cessation of growth hormone therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth.
J Clin Endocrinol Metab, 88 (2003), pp. 1658-1663
[38.]
L. Wiren, B.A. Bengtsson, G. Johannsson.
Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency.
Clin Endocrinol (Oxf), 48 (1998), pp. 613-620
[39.]
T. Rosen, L. Wiren, L. Wilhelmsen, I. Wiklund, B.A. Bengtsson.
Decreased psychological well-being in adult patients with growth hormone deficiency.
Clin Endocrinol (Oxf), 40 (1994), pp. 111-116
[40.]
R.D. Murray, C.J. Skillicorn, S.J. Howell, C.A. Lissett, A. Rahim, M. Shalet.
1999 Influences on quality of life in GH deficient adults and their effect on response to treatment.
Clin Endocrinol, 51 (1999), pp. 565-573
[41.]
T. Rosen, S. Eden, G. Larson, L. Wilhelmsen, B.A. Bengtsson.
Cardiovascular risk factors in adult patients with growth hormone deficiency.
Acta Endocrinol (Copenh), 129 (1993), pp. 195-200
[42.]
B. Angelin, M. Rudling.
Growth hormone and hepatic lipoprotein metabolism.
Curr Opin Lipid, 5 (1994), pp. 160-165
[43.]
S. Webb, A. Lloveras, A. Caballero, A. Pérez, F. Blanco, A. Wagner, et al.
Riesgo aterogénico en la deficiencia de hormona de crecimiento en el adulto.
Endocrinol Nutr, 46 (1999), pp. 322-325
[44.]
J.U. Weaver, J.P. Monson, K. Noonan, W.G. John, A. Edwards, K.A. Evans, et al.
The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.
J Clin Endocrinol Metab, 80 (1995), pp. 153-159
[45.]
H.M. Whitehead, C. Boreham, E.M. MaIlrath, B. Sheridan, L. Kennedy, A.B. Atkinsons, et al.
Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross over study.
Clin Endocrinol (Oxf), 36 (1992), pp. 45-52
[46.]
J. Koranyi, J. Svensson, G. Gotherstrom, K.S. Sunnerhagen, B. Bengtsson, G. Johannsson.
Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative prospective study.
J Clin Endocrinol Metab, 86 (2001), pp. 4693-4699
[47.]
S. Edén, O. Wiklund, J. Oscarsson, T. Rosén, B. Bengtsson.
Growth hormone treatment of growth hormone deficient adults results in a marked increase of Lp(a) and HDL colesterol concentrations.
Atherosclerosis, 133 (1997), pp. 115-121
[48.]
W. Nolte, C. Radisch, V.W. Armstrong, M. Hufner, A. Von zur Muhlen.
The effect of recombinant human GH replacement therapy on lipoprotein (a) and other lipid parameters in adults with acquired GH deficiency: results of a double-blind and palacebo-control trial.
Eur J Endocrinol, 137 (1997), pp. 459-466
[49.]
R. Kuramaru, H. Kohno, N. Ueyame, H.N. Hassan, S. Honda, T. Hara.
Long-term prospective study of body composition and lipid profiles during and after growth hormone treatment in children with GH deficiency: gender-specific metabolic effects.
J Clin Endocrinol Metab, 83 (1998), pp. 3890-3896
[50.]
A. Colao, P. Marzullo, C. Di Somma, G. Lombardi.
Growth hormone and the heart.
Clin Endocrinol (Oxf), 54 (2001), pp. 137-154
[51.]
T. Rosen, B.A. Bengtsson.
Premature mortality due to cardiovascular disease in hypopituitarism.
Lancet, 336 (1990), pp. 285-288
[52.]
A. Sanmartí.
Morbimortalidad cardiovascular en el hipopituitarismo. ¿Hay evidencias de que pueda atribuirse al déficit de hormona de crecimiento?.
Endocrinol Nutr, 49 (2002), pp. 213-216
[53.]
L. Thuesen, J.O. Jorgensen, B.O. Muller JR Kristensen, N.E. Skakkebaek, N. Vahl, et al.
Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults.
Clin Endocrinol (Oxf), 41 (1994), pp. 615-620
[54.]
R. Valcavi, O. Gaddi, M. Zini, M. Lavicoli, U. Mellino, I. Portioli.
Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment.
J Clin Endocrinol Metab, 80 (1995), pp. 659-666
[55.]
S. Longobardi, A. Cuocolo, B. Merola, F. Left Di Rella, A. Colao, et al.
Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency.
Clin Endocrinol (Oxf), 48 (1998), pp. 137-143
[56.]
A. Colao, C. di Somma, A. Cuocolo, L. Spinelli, N. Tedesco, R. Pivonello, et al.
Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.
J Clin Endocrinol Metab, 86 (2001), pp. 1874-1881
Copyright © 2003. Sociedad Española de Endocrinología y Nutrición
